Miriam Merad, MD, PhD, is the Chair of the Department of Immunology and Immunotherapy, the Director of the Marc and Jennifer Lipschultz Precision Immunology Institute at Mount Sinai School of Medicine in New York and the Director of the Mount Sinai Human Immune Monitoring Center (HIMC).
Dr. Merad is an internationally acclaimed physician-scientist and a leader in the fields of dendritic cell and macrophage biology with a focus on their contribution to human diseases. Dr. Merad identified the tissue resident macrophage lineage and revealed its distinct role in organ physiology and pathophysiology. She established the contribution of this macrophage lineage to cancer progression and inflammatory diseases and is now working on the development of novel macrophage-targeted therapies for these conditions. In addition to her work on macrophages, Dr. Merad is known for her work on dendritic cells, a group of cells that control adaptive immunity. She identified a new subset of dendritic cells, which is now considered a key target of antiviral and antitumor immunity.
Dr. Merad leads the Precision Immunology Institute at the Icahn School of Medicine (PrIISM) to bring immunology discoveries to the clinic. PrIISM integrates immunological research programs with synergistic expertise in biology, medicine, technology, physics, mathematics and computational biology to enhance our understanding of human immunology. She also founded the Human Immune Monitoring Center at Mount Sinai, one of the world’s most sophisticated research centers, which uses cutting-edge single-cell technology to understand the contribution of immune cells to major human diseases or treatment responses.
Dr. Merad has authored more than 200 primary papers and reviews in high profile journals. Her work has been cited several thousand times. She receives generous funding from the National Institutes of Health (NIH) for her research on innate immunity and their contribution to human disease, and belongs to several NIH consortia. She is an elected member of the American Society of Clinical Investigation and the recipient of the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology. She is the President-elect of the International Union of Immunological Societies (IUIS). In 2020, she was elected to the National Academy of Sciences in recognition of her contributions to the field of immunology.
Please visit Dr. Merad's Lab website:
Title |
Cited By |
Year |
---|
Miriam Merad, MD, PhD, an esteemed immunologist at the Icahn School of Medicine at Mount Sinai, has been elected to the National Academy of Medicine (NAM) in recognition of her pioneering contributions to the fields of immunology and cell biology.
09-Oct-2023 10:30:40 AM EDT
Mount Sinai scientists have developed a new technology allowing them to link specific genes to complex tumor characteristics at a scale and resolution not previously possible. The results could lead to new approaches for targeting anti-cancer drugs.
15-Mar-2022 10:50:00 AM EDT
New research is showing the profound benefits—for longevity and fighting disease—of intermittent fasting
15-Aug-2019 10:30:15 AM EDT
Miriam Merad, MD, PhD, Director of the Precision Immunotherapy Institute and the program leader of the Cancer Immunology and Immunotherapy Group at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, has received the Cancer Research Institute’s top honor, one previously awarded to two Nobel laureates, for her contributions to cancer immunology and immunotherapy.
25-Oct-2018 06:00:03 AM EDT